Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Tencent Holdings ADR TCEHY

Tencent Holdings Ltd is an investment holding company primarily engaged in the provision of value-added services (VAS), online advertising services, as well as FinTech and business services. The Company primarily operates through four segments. The VAS segment is mainly engaged in the provision of online games, video account live broadcast services, paid video membership services and other social network services. The Online Advertising segment is mainly engaged in media advertising, social and other advertising businesses. The FinTech and Business Services segment mainly provides commercial payment, FinTech and cloud services. The Others segment is principally engaged in the investment, production and distribution of films and television program for third parties, copyrights licensing, merchandise sales and various other activities.


OTCPK:TCEHY - Post by User

Post by Alfonsouon Jun 03, 2022 4:42am
108 Views
Post# 34728712

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.

<< Previous
Bullboard Posts
Next >>